Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, cash reserves at Oruka Therapeutics Inc fell by 5.01m. However, Cash Flow from Investing was flat, indicating that little new money was committed to growth. In addition the company used 5.01m for operations while cash from financing was breakeven.
Cash flow per share | -5.96 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 26.94 |
---|---|
Tangible book value per share | 26.94 |
More ▼
Balance sheet in USDView more
Current ratio | 26.61 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼